Enamine to Enable Access to Selected Pfizer Reference Compounds to Support the Global Research Community

KYIV, UKRAINE, May 26, 2025 /EINPresswire.com/ -- Enamine, the leading provider of chemical compounds and drug discovery services, today announced certain reference compounds from Pfizer are now available through Enamine`s marketplace and Enamine`s integration capabilities (i.e. punchout site, hosted catalogs, and API solutions). This allows researchers to explore and purchase from the catalog of selected Pfizer-provided drugs, chemical dormants, investigational compounds, and isotope-labelled molecules with appropriate quality control.

Iryna Yavnyuk, CEO of Enamine US, Inc. comments: “For over 30 years, Enamine has remained the world’s leading provider of small molecules, having the largest in-stock catalog of screening compounds and building blocks. Our goal has remained the same over the years: support research programs around the world to contribute to global science. Having added selected Pfizer-provided compounds to our offerings, we will make sure our customers will have access to a broader diversity of chemicals in one place.”

𝐀𝐛𝐨𝐮𝐭 𝐄𝐧𝐚𝐦𝐢𝐧𝐞: Enamine is a scientifically driven integrated discovery Contract Research Organisation with unique partnering opportunities in exploring new chemical space. The company combines access to the in-house produced screening compounds (4.5M in stock) and building blocks (350K in stock) with a comprehensive platform of integrated discovery services to advance and accelerate the efforts in Drug Discovery. For more information visit: https://enamine.net

Iryna Yavnyuk
Enamine
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.